Adult T-cell leukemia future or investigational therapies: Difference between revisions
(Created page with "__NOTOC__ {{Adult T-cell leukemia}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== ...") |
No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Adult T-cell leukemia}} | {{Adult T-cell leukemia}} | ||
Molecular [[Target therapy|targeting therapy]] like targeting therapy against ''NOTCH1''/''FBXW7'' mutations, [[JAK|JAK-STAT]] signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.<ref name="pmid25966987">{{cite journal |vauthors=Litzow MR, Ferrando AA |title=How I treat T-cell acute lymphoblastic leukemia in adults |journal=Blood |volume=126 |issue=7 |pages=833–41 |date=August 2015 |pmid=25966987 |doi=10.1182/blood-2014-10-551895 |url=}}</ref><ref name="pmid25193870">{{cite journal |vauthors=Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J |title=JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model |journal=Blood |volume=124 |issue=20 |pages=3092–100 |date=November 2014 |pmid=25193870 |doi=10.1182/blood-2014-04-566687 |url=}}</ref><ref name="pmid22516257">{{cite journal |vauthors=Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG |title=Targeting nonclassical oncogenes for therapy in T-ALL |journal=Cancer Cell |volume=21 |issue=4 |pages=459–72 |date=April 2012 |pmid=22516257 |doi=10.1016/j.ccr.2012.02.029 |url=}}</ref> | |||
== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 12: | Line 10: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pathology]] | [[Category:Pathology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 18:44, 25 November 2018
|
Adult T-cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adult T-cell leukemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Adult T-cell leukemia future or investigational therapies |
|
FDA on Adult T-cell leukemia future or investigational therapies |
|
CDC on Adult T-cell leukemia future or investigational therapies |
|
Adult T-cell leukemia future or investigational therapies in the news |
|
Blogs on Adult T-cell leukemia future or investigational therapies |
|
Risk calculators and risk factors for Adult T-cell leukemia future or investigational therapies |
Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.[1][2][3]
- ↑ Litzow MR, Ferrando AA (August 2015). "How I treat T-cell acute lymphoblastic leukemia in adults". Blood. 126 (7): 833–41. doi:10.1182/blood-2014-10-551895. PMID 25966987.
- ↑ Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J (November 2014). "JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model". Blood. 124 (20): 3092–100. doi:10.1182/blood-2014-04-566687. PMID 25193870.
- ↑ Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG (April 2012). "Targeting nonclassical oncogenes for therapy in T-ALL". Cancer Cell. 21 (4): 459–72. doi:10.1016/j.ccr.2012.02.029. PMID 22516257.